Subscribe
shutterstock_1757758247_oasis2me
oasis2me / Shutterstock.com
8 March 2022BiotechnologyTakanori Abe

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Issue: Report of the Japan Biosimilar Association

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More features

Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
AstraZeneca unit draws line under Samsung dispute
Does the UPC offer a fresh take on patent validity?
Regeneron targets almost 50 patents in suit against Sandoz
Litigation implications of the USPTO’s terminal disclaimer proposal
Ipsen files further suit against CSPC over pancreatic cancer drug generic